AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36435233
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with antithrombotic drugs
Trial: 33466183
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg, maximum dose 24 mg)
Trial: 32580752
Drug: Shenhuang granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenhuang granule treatment twice a day for 14 days
Trial: 33865841
Drug: 16.25 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.25 g fiber diet
Trial: 33865841
Drug: 32.5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32.5 g fiber diet
Trial: 32119821
Drug: Shortened mosaic
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shortened mosaic HIV‐1 vaccine schedules
Trial: 35369762
Drug: Conventional physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy (CPT) treatment
Trial: 32641343
Drug: Intravenous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high-dose vitamin C (HIVC) diluted in sterile water for 7 days
Trial: 32774912
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg)
Trial: 32619609
Drug: sprifermin 100
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprifermin 100 μg q6mo
Trial: 33019480
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy combined with multiple drilling and intramedullary drug injection (group EMI)
Trial: 33019480
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (group E)
Trial: 33019480
Drug: Multiple drilling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple drilling combined with intramedullary drug injection (group MI)
Trial: 39089652
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation
Trial: 32644833
Drug: Low-dose ER-MPH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ER-MPH (0.21 mg/kg equivalent of IR-MPH)
Trial: 32644833
Drug: Medium-dose ER-MPH
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose ER-MPH (0.35 mg/kg equivalent of IR-MPH)
Trial: 32644833
Drug: High-dose ER-MPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ER-MPH (0.48 mg/kg equivalent of IR-MPH)
Trial: 33015164
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with antipsychotic medication
Trial: 34874836
Drug: Tocilizumab treatment
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab treatment
Trial: 32320845
Drug: Tablet-assisted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet-assisted intervention (SPARK) consisting of interactive games and activities to improve provider fidelity and child engagement in evidence-based psychotherapies.
Trial: 32233741
Drug: Early antihypertensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antihypertensive treatment
Trial: 34048504
Drug: PfSPZ-CVac (5.12x10^4)
RxNorm normalized name: CVac
DrugBank: CVac (DB17351)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ-CVac (5.12x10^4) administered via three direct venous inoculations (DVIs) seven days apart
Trial: 34048504
Drug: PfSPZ-CVac (1.024x10^5)
RxNorm normalized name: CVac
DrugBank: CVac (DB17351)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ-CVac (1.024x10^5) administered via three direct venous inoculations (DVIs) five days apart
Trial: 34048504
Drug: PfSPZ-CVac (5.12x10^4)
RxNorm normalized name: CVac
DrugBank: CVac (DB17351)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ-CVac (5.12x10^4) administered via three injections five days apart (previous study)
Trial: 33811250
Drug: Peg-interferon-α (peg-IFN-α)
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-interferon-α (peg-IFN-α) add-on treatment
Trial: 33811250
Drug: Peg-interferon-α (peg-IFN-α)
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-interferon-α (peg-IFN-α) switch treatment
Trial: 33811250
Drug: Peg-interferon-α (peg-IFN-α)
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-interferon-α (peg-IFN-α) therapy (both add-on and switch)
Trial: 34007066
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy (LiST)
Trial: 33593287
Drug: Mobile e‐learning,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile e‐learning, mentor‐led online social support networking, and monthly face‐to‐face mentoring support group meetings
Trial: 32723294
Drug: HDF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDF group (once and twice weekly HDF)
Trial: 32723294
Drug: Twice HDF
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice HDF subgroup
Trial: 38176391
Drug: Schema Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema Therapy (ST)
Trial: 34826668
Drug: Dienogest (Visanne)
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest (Visanne) 2 mg/day
Trial: 34826668
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (Yasmin, 0.03 mg ethinyl estradiol and 3 mg drospirenone)
Trial: 33960309
Drug: Spironolactone (1:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (1:1 placebo-controlled treatment)
Trial: 34511181
Drug: Psychoeducational/behavioral treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational/behavioral treatments
Trial: 34511181
Drug: Neuromodulation treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulation treatments
Trial: 38296290
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous fumarate
Trial: 32942914
Drug: Daily mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mobile phone instructional text messages with standard care
Trial: 32564438
Drug: Resveratrol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (75 mg twice daily)
Trial: 33486869
Drug: High-phosphorus diet
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-phosphorus diet (HPD): 2300 mg/d
Trial: 36200646
Drug: High-dose dual-impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual-impregnated antibiotic-loaded cement (DIAC) including gentamicin and clindamycin
Trial: 36200646
Drug: Low-dose single-impregnated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose single-impregnated gentamicin antibiotic-loaded cement (SIAC)
Trial: 33795330
Drug: Tofacitinib (TOFA)
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib (TOFA) 5mg twice daily
Trial: 33905281
Drug: Exposure-Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-Focused Cognitive Behavioral Therapy (EF-CBT)
Trial: 33631500
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg, orally once daily in the morning)
Trial: 33631500
Drug: Placebo (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orally once daily in the morning)
Trial: 35268027
Drug: High NO3-
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NO3- (2 × 70 mL beetroot juice/day)
Trial: 35268027
Drug: Medium NO3-
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium NO3- (70 mL beetroot juice/day)
Trial: 35268027
Drug: Low NO3-
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low NO3- (70 mL beetroot juice on alternate days)
Trial: 35268027
Drug: Placebo (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (70 mL of NO3--depleted beetroot juice on alternate days)
Trial: 32209983
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester drink ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate, 482 mg/kg body mass)
Trial: 33550228
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-intensity interval training and time-restricted eating
Trial: 34625396
Drug: Educational flyer
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational flyer and monthly HTN education messages for one year (Case group)
Trial: 33126100
Drug: Common Elements
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common Elements Treatment Approach (CETA) intervention
Trial: 39209187
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg once daily
Trial: 34224256
Drug: Levothyroxine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine therapy
Trial: 32024584
Drug: CPAP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP + Behavioral Sleep Medicine (BSM) intervention targeting physical activity and eating behavior changes
Trial: 32536331
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg lorazepam
Trial: 33592176
Drug: Cabozantinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (60 mg daily, with dose reductions to 40 mg and 20 mg allowed)
Trial: 33592176
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg, 4 weeks on and 2 weeks off, with dose reductions to 37.5 mg and 25 mg allowed)
Trial: 33592176
Drug: Crizotinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (250 mg twice daily, with dose reductions to 200 mg twice daily and 250 mg once daily allowed)
Trial: 33592176
Drug: Savolitinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib (600 mg daily, with dose reductions to 400 mg and 200 mg allowed)
Trial: 32981068
Drug: Cysteamine cream
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine cream
Trial: 33625939
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of promethazine
Trial: 34110605
Drug: secukinumab 150/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 150/300 mg
Trial: 33141935
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with immediate provisionalization (Group A: n = 20)
Trial: 33141935
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with delayed provisionalization (Group B: n = 20)
Trial: 33770684
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg finerenone
Trial: 32607644
Drug: LCIG infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LCIG infusion plus three oral doses of placebo
Trial: 32607644
Drug: Oral immediate-release
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immediate-release carbidopa/levodopa (LC-IR)
Trial: 33278599
Drug: S-1 (40-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (40-60 mg twice daily for 4 weeks on/2 weeks off for 1 year)
Trial: 33278599
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus oxaliplatin (SOX) (130 mg/m2 every 3 weeks for 6 months)
Trial: 33402624
Drug: Minimal excavation
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal excavation and LSTR with triple antibiotic paste (TAP)
Trial: 33402624
Drug: Traditional indirect
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional indirect pulp treatment with calcium hydroxide
Trial: 33002377
Drug: Leg heat
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leg heat therapy (HT) 3 times/week for 6 weeks using water-circulating trousers at 48°C
Trial: 33369253
Drug: Leg heat
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leg heat therapy (HT)
Trial: 32892987
Drug: Single Antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Antiplatelet Therapy (SAPT)
Trial: 34910278
Drug: Dual Antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual Antiplatelet Therapy (DAPT)
Trial: 34142951
Drug: Generic metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic metformin hydrochloride (850 mg)
Trial: 34142951
Drug: Glucophage (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucophage (reference preparation)
Trial: 32076783
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) treatment
Trial: 32564889
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy followed by preoperative chemotherapy and surgery
Trial: 32464334
Drug: 4-valent HPV
RxNorm normalized name: HPV, bivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-valent HPV vaccine (6/11/16/18)
Trial: 36431312
Drug: Conventional NEURO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional NEURO® occupational therapy
Trial: 32053984
Drug: Walnut group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut group (1, 1.5, or 2 oz. of walnuts daily)
Trial: 35438586
Drug: Integrated Behavior
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Behavior Therapy for Children with Selective Mutism (IBTSM)
Trial: 32451241
Drug: ACTitouch adaptive
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTitouch adaptive compression therapy (ACT) system
Trial: 34491021
Drug: Kynurenic acid
RxNorm normalized name: Kynurenic Acid
DrugBank: Kynurenic Acid (DB11937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kynurenic acid 0.5% (FS2) cream (Group 1)
Trial: 34491021
Drug: Active onion
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active onion extract comparator treatment (Group 2)
Trial: 32026257
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 0 ng·ml‐1
Trial: 32026257
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 1 ng·ml‐1
Trial: 32026257
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 3 ng·ml‐1
Trial: 32026257
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 5 ng·ml‐1
Trial: 32050055
Drug: Naltrexone HCl
RxNorm normalized name: naltrexone HCl
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone HCl (10 mg)
Trial: 32050055
Drug: Nalmefene HCl
RxNorm normalized name: nalmefene HCl
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nalmefene HCl (10 mg)
Trial: 36277907
Drug: Pimavanserin 34
RxNorm normalized name: pimavanserin 34 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin 34 mg
Trial: 33773103
Drug: Buprenorphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine plus naloxone therapy
Trial: 33539760
Drug: Referral for
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral for methadone maintenance therapy
Trial: 35717608
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance (IR)
Trial: 34951474
Drug: Warrior Programme
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warrior Programme intervention (Time Line Therapy™)
Trial: 32888826
Drug: 2.5mg inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg inhaled lancovutide (once daily, every other day or twice a week) for eight weeks
Trial: 33472052
Drug: Catheter ablation-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter ablation-based AF rhythm control with optimal HF therapy and aggressive catheter ablation (PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug)
Trial: 33472052
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate control with optimal HF therapy and measures to achieve resting HR < 80 bpm and 6-minute walk HR < 110 bpm
Trial: 35029187
Drug: antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antihypertensive drugs + acupuncture
Trial: 35029187
Drug: antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antihypertensive drugs + sham acupuncture
Trial: 33773580
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (40 mg.kg−1 bolus and 20 mg.kg−1.h−1 infusion)
Trial: 33773580
Drug: Lidocaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (3 mg.kg−1 bolus and 3 mg.kg−1.h−1 infusion)
Trial: 33773580
Drug: Magnesium plus
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium plus lidocaine (equal doses of both drugs)
Trial: 33773580
Drug: Control (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isotonic solution)
Trial: 32564649
Drug: SHARe program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHARe program (weekly eight-session, 12-hour group program)
Trial: 33169490
Drug: Unguided Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided Internet-based cognitive-behavioral therapy (iCBT)
Trial: 36460266
Drug: Family-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Based Treatment (FBT-ARFID)
Trial: 36460266
Drug: Psychoeducational Motivation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational Motivation Therapy (PMT)
Trial: 33244458
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg/d
Trial: 34758252
Drug: Sacubitril-valsartan (97
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily)
Trial: 32259228
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus Olaratumab (75 mg/m2 + 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles)
Trial: 32259228
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus Placebo (75 mg/m2 + placebo)
Trial: 37102974
Drug: Loop diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics
Trial: 34480008
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (SB; 0.3 g/kg body mass) with high-intensity (HI) warm-up
Trial: 34480008
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (SB; 0.3 g/kg body mass) with low-intensity (LI) warm-up
Trial: 36148560
Drug: Hypothetical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical treatment to reduce exacerbation rate
Trial: 32144167
Drug: Smart bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart bolus calculator informed by real-time insulin sensitivity estimates
Trial: 35401774
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment (PT)
Trial: 35918696
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anesthetic (IA)
Trial: 32109991
Drug: Fixed-Dose Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-Dose Combination (FDC) of amlodipine/losartan/rosuvastatin 5/100/20 mg